Home › NCT04052048
Active Surveillance SNEP Assay Registry Trial for Prostate Cancer
RecruitingObservational study
A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.
Who can join
Ages 40 to 80 · Men
Full eligibility criteria
Inclusion Criteria * Men between 40-80 of age with at least a 10-year life expectancy * All active surveillance protocols are accepted * No PSA limits Category 1: * Patient is currently on active surveillance with only ONE previous low grade prostate biopsy. * Patient must already be scheduled for their 1st annual biopsy under their active surveillance protocol within 90 days of enrollment date. Category 2: • Patient is recently diagnosed with low grade prostate cancer but has decided against active surveillance and is scheduled for radical prostatectomy within 90 days of enrollment date. Exclusion Criteria: Men on watchful waiting i.e. those with less than 10-year life expectancy with no intent for curative therapy * Men with symptoms or rising PSA who have not been proven to have cancer by tissue biopsy i.e. men with only negative prostate biopsies. * Patients with a history of a different cancer (except basal cell carcinoma)
About the study
A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.
What is being tested
- Subtraction Normalized Expression of Phagocytes Blood Test (diagnostic test)
Sponsor: Immunis.AI · Participants: 2,000 · Started: Sep 9, 2019
Contact the study team
- Jessica DeHart · Phone: 619-316-1416
Official record on ClinicalTrials.gov — NCT04052048
Locations in the U.S.
| Michigan | Comprehensive Urology, Royal Oak |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.